Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Aclara BioSciences and Tokyo Metropolitan Institute

June 17th, 2004

Aclara BioSciences and Tokyo Metropolitan Institute

Abstract:
Aclara BioSciences Inc. and the Tokyo Metropolitan Institute of Medical Science (Rinshoken) announced today that they have entered into an agreement to collaborate on a study to evaluate breast cancer patient samples to validate candidate biomarkers detected with ACLARA's proprietary eTag(TM) technology. This study follows previously completed feasibility experiments on a small set of tissue samples from patients treated with Genentech's drug Herceptin(R) and chemotherapy.

Source:
Aclara BioSciences

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Remote-control shoots laser at nano-gold to turn on cancer-killing immune cells April 20th, 2018

Observing biological nanotransporters: Chemistry April 19th, 2018

Nanobiotix Shows NBTXR3 Nanoparticles Can Stoke Anti-Tumor Immune Response April 17th, 2018

Tiny nanomachine successfully completes test drive: Researchers at the University of Bonn and the research institute Caesar build a one-wheeled vehicle out of DNA rings April 11th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project